-
New data released on pozytinib, revealing insertion site analysis and secondary resistance mechanisms
Time of Update: 2022-08-19
Recently, "Cancer Cell" published the results of a phase II clinical study of Poziotinib (Chinese temporary translation of poziotinib, R&D number HM781-36B, online nickname 781, hereinafter referred t
-
J Clin Oncol: Rituximab + Lenalidomide + Ibrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Time of Update: 2022-08-19
This is an investigator-initiated, single-arm, Phase 2 clinical trial that enrolled 60 patients with newly diagnosed non-germinal center B-cell-like DLBCL to receive rituximab (375 mg/m2, day 1) , lenalidomide (25 mg/day, days 1-10) and ibrutinib (560 mg/day) (RLI) were treated sequentially, with 21 days as a course of treatment .
-
European Radiology: Optimal response time point for predicting survival is associated with tumor burden after TACE for hepatocellular carcinoma
Time of Update: 2022-08-19
A Survival of initial responders versus non-responders in the low tumor burden stratum .
B Survival of best responders versus non-responders in the low tumor burden stratum .
F Survival of best responders versus non-responders in the high tumor burden stratum .
-
Express for the most common breast cancer, Trop-2 targeting ADC significantly prolongs patients' lives
Time of Update: 2022-08-19
▎Edited by WuXi AppTec Content TeamGilead Sciences today announced that its antibody-drug conjugate Trodelvy (sacituzumab govitecan) significantly improved overall overall outcomes in a Phase 3 trial of TROPiCS-02 in patients with HR-positive/HER2-negative metastatic breast cancer who had received multiple prior therapies.
-
Lancet Oncol: Duvalumab and Tremelimumab in Advanced Metastatic Sarcoma
Time of Update: 2022-08-19
This is a single-center, phase 2 trial that enrolled patients 18 years of age and older with at least one prior systemic therapy with advanced or metastatic sarcoma with an ECOG performance status of 0-1 who received intravenous duvalumab ( 1500 mg) and tremelimumab (75 mg) for 4 cycles, followed by maintenance duvalumab (1 time/4 weeks) for 12 months .
-
Blood: Gilteritinib plus azacitidine vs azacitidine alone in newly diagnosed FLT3mut+ AML
Time of Update: 2022-08-19
The study is a multicenter, open-label, phase 3 randomized trial that enrolled previously untreated patients with FLT3 mut+ AML who were not candidates for intensive induction chemotherapy, randomized 2:1 to gilteritinib (120 mg) / day, oral) + azacitidine group (GIL + AZA) or azacitidine alone group (AZA) .
-
One article to understand the image interpretation and identification points of common mediastinal tumors
Time of Update: 2022-08-19
Imaging appearance of bronchial cystImaging appearance of pericardial cystDifferentiation points of mediastinal tumor and paramediastinal lung cancer The mediastinum is located in the middle of the thoracic cavity, surrounded by the lungs on both sides, and is divided into superior, anterior, middle, and posterior mediastinum .
-
How to judge whether IASLC lung cancer surgery is completely removed?
Time of Update: 2022-08-19
Incomplete resection or indeterminate resection will significantly reduce the survival time, so how to judge whether it is a complete resection?IASCL DefinitionIn 2005, the International Association for the Study of Lung Cancer (IASLC Staging Committee) proposed "complete resection (complete rep)", "incomplete resection (incomplete rep)", "indeterminate resection" based on previous definitions and understandings.
-
European Radiology: Long-term outcomes of ablation and laparoscopic partial nephrectomy in the treatment of T1 renal cell carcinoma
Time of Update: 2022-08-19
A study published in the European Radiology journal provides 10 years of experience and evidence from our institution for the treatment of biopsy- or histologically confirmed T1aN0M0 and T1bN0M0 renal cell carcinoma (RCC) patients undergoing imaging-guided CRYO or RFA and LPN provides clinical guidance on long-term oncological prognosis .
-
Radiology: The value of multiparametric MRI for risk stratification of renal masses
Time of Update: 2022-08-19
Recently, a study published in the journal Radiology evaluated the performance and inter-observer agreement of the ccLS system in diagnosing ccRCC in solid SRM, and provided clinical evidence for accurate risk stratification and personalized treatment of such patients.
-
Quickly learn abdominal CT in ten minutes, and understand it in seconds!
Time of Update: 2022-08-19
0cm can be seen in the lateral segment of the left hepatic lobe, with a clear boundary and a high density.
0cm can be seen in the lateral segment of the left hepatic lobe, with a clear boundary and a high density.
-
They are "food assassins" hidden on the dining table, nourishing cancer cells with every bite!
Time of Update: 2022-08-19
Even Chinese-style salted fish containing type 1 carcinogens does not cause cancer after eating once, but if you eat a large amount every day, the risk of nasopharyngeal cancer will increase over time .
-
Lancet Oncol: Adaptive de-escalation of radiotherapy based on recurrence risk after initial chemotherapy for cT1-2N1 breast cancer
Time of Update: 2022-08-19
The aim of this study was to assess the oncological safety of de-escalated local radiotherapy in patients with cT1-2N1 breast cancer receiving primary chemotherapy according to pre-determined, consensus-based research guidelines .
-
Shengbai needle is often used, do you know these common adverse reactions?
Time of Update: 2022-08-19
Shengbai needle, recombinant human granulocyte colony-stimulating factor (G-CSF), its role is to promote the immature neutrophils in the bone marrow to mature, differentiate and proliferate as soon as possible, and spread to the peripheral blood to increase the leukocyte count.
-
Will needle biopsy lead to tumor metastasis?
Time of Update: 2022-08-19
For example, the detection rate of prostate cancer biopsy is low, and multiple needles and multiple sites are often needed to improve the accuracy of diagnosis .
-
Nature Communications: Zhejiang University Xie Anyong's team reveals the origin and mechanism of the characteristic mutation pattern of BRCA1-deficient tumors
Time of Update: 2022-08-19
Xie Anyong from the Institute of Translational Medicine / Run Run Shaw Hospital Affiliated to the School of Medicine of Zhejiang University published a research paper entitled: DNA nicks induce mutational signatures associated with BRCA1 deficiency in the journal Nature Communications .
-
How to choose the second-line treatment for advanced NSCLC immunotherapy combined with chemotherapy (IO-CT) resistance?
Time of Update: 2022-08-19
06-Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC) The IO-CT combination has become the standard of care for patients with aNSCLC with low or moderate programmed death ligand 1 (PD-L1) expression ( 6 months .
-
Misdiagnosis analysis: such a solid mass with many malignant features is actually benign, why?
Time of Update: 2022-08-19
(The article contains surgical specimens, for the purpose of expressing the content of the case for popular science, please choose carefully and click to read)Patient A, male, 65 years old, is the fat
-
Eight people in the family have cancer and the second-born mother is also diagnosed with cancer. Can cancer be inherited?
Time of Update: 2022-08-19
" The doctor reminded: If there are multiple or the same tumor patients in members of different generations in the family, pay attention and do Early detection, early prevention, early diagnosis and early treatment .
-
Case sharing (2022.7.30): It has been proved many times that the pulmonary ground glass nodule with such characteristics is a minimally invasive adenocarcinoma
Time of Update: 2022-08-19
There was a ground-glass nodule in the upper lobe of the left lung, and the density was not high, but there were blood vessels running through it, and the surface was uneven, which seemed to have a superficial lobulation sign .
